Home/Filings/4/0001567619-21-017751
4//SEC Filing

SCHAFFER DAVID 4

Accession 0001567619-21-017751

CIK 0001650648other

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 4:34 PM ET

Size

13.3 KB

Accession

0001567619-21-017751

Insider Transaction Report

Form 4
Period: 2021-09-29
SCHAFFER DAVID
Director10% Owner
Transactions
  • Sale

    Common Stock

    2021-09-29$29.06/sh8,365$243,058950,585 total
  • Sale

    Common Stock

    2021-09-29$30.06/sh700$21,044949,885 total
  • Sale

    Common Stock

    2021-09-29$27.99/sh7,806$218,512958,950 total
  • Sale

    Common Stock

    2021-09-30$26.69/sh7,836$209,165942,049 total
  • Sale

    Common Stock

    2021-09-30$27.28/sh4,549$124,085937,500 total
Footnotes (6)
  • [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The transaction was executed in multiple trades in prices ranging from $27.70 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]The transaction was executed in multiple trades in prices ranging from $28.71 to $29.69, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F4]The transaction was executed in multiple trades in prices ranging from $29.75 to $30.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F5]The transaction was executed in multiple trades in prices ranging from $26.07 to $27.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F6]The transaction was executed in multiple trades in prices ranging from $27.08 to $27.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file

Issuer

4D Molecular Therapeutics Inc.

CIK 0001650648

Entity typeother

Related Parties

1
  • filerCIK 0001692929

Filing Metadata

Form type
4
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 4:34 PM ET
Size
13.3 KB